The Insider: Meet the CEOs Webcast Replay
We were joined by the CEOs of exciting ASX-listed businesses, who gave valuable insight to their industries and companies future prospects.
- (ASX: CCR) Credit Clear Limited – Andrew Smith
- (ASX: RAC) Race Oncology Limited – Daniel Tillett
Recorded on 9th November 2022 at 12pm (AEDT).
FEATURED SPEAKERS
Andrew Smith
CEO - Credit Clear (ASX: CCR)
Credit Clear owns a communications platform that has attracted investments from some of Australia’s leading fund managers – from Alex Waislitz’s Thorney Investment Group, to Ellerston Capital. The company has grown its revenue at a 183% CAGR between FY18 and FY22 with the acquisition of two businesses and has experienced growth across all parts of the business. Credit Clear won ‘Best Use of AI’ at the 7th and 8th Annual Australian Fintech Awards and was also an ‘Insurtech Start-up of the Year’ finalist at the 2022 Australian and New Zealand Institute of Insurance and Finance awards. The company provides services to some of Australia’s largest companies, including TPG Telecom, Suncorp, Water Corporation and more.
Daniel Tillett
Chief Scientific Officer - Race Oncology (ASX: RAC)
Race Oncology is a precision oncology company with a lead drug, Zantrene, capable of targeting a potential 15% of all cancers within the total estimated US$272 billion (by 2030) global cancer drug market. Aussie biotech investor Andrew Merchant (Merchant Funds) noted in October that the company had a balance sheet with ~$40 million in cash, skin-in-the-game and stock buyback factors and more. The company is led by a seasoned team and board supported by a network of key opinion leaders and collaborators, including Phillip Lynch, Dr John Cullity and Professor Borje Andersson. Race has also identified an independent US$10 billion market opportunity for Zantrene in preventing heart damage caused by chemotherapy.
